PhRMA Seeks Quick Win In 340B Orphan Drug Suit

Law360, New York (February 26, 2015, 7:29 PM ET) -- Pharmaceutical Research and Manufacturers of America on Wednesday urged a D.C. federal judge to ax a regulation involving discounts for orphan drugs, setting the stage for an important decision on the 340B programâ€™s future.



In a motion for summary judgment, PhRMA targeted a so-called interpretive rule issued last year by the U.S. Department of Health and Human Services to require discounts when orphan drugs for rare diseases are used for common ailments. HHS says the rule isn't final agency action subject to judicial review, but PhRMA...

To view the full article, register now.